Pharmacokinetics of Norvancomycin of SICU Patients
SUN Na1，2，ZHANG Zhen-yu3，AN You-zhong3，ZHANG Chun-yan1，GU Jian1*
Author information+
1.Department of Pharmacy， Peking University People′s Hospital， Beijing 100044 ; 2 . Department of Pharmacy Administration and Clinical Pharmacy， Peking University School of Pharmaceutical Science， Beijing 100083； 3 .Department of SICU， Peking University People′s Hospital， Beijing 100044
OBJECTIVE To study pharmacokinetics of norvancomycin in SICU severe patients without liver or renal dysfunction. METHODS 9 SICU severe patients were given a single dose of 0.4 g iv norvancomycin. The plasma and urine concentrations were determined with HPLC， and PK parameters were analyzed by WINNONLIN. RESULTS The pharmacokinetic parameters in plasma were as followed：t1/2β(4.79±2.61 h，t1/2α ( 0.69±0.33 h，Vd(0.41±0.44 L·kg-1，k10(0.45±0.26 h-1，ρmax(23.46±13.69 mg·L-1，and CL(88.66±69.04 mL·min-1 . The pharmacokinetic parameters in urine were as followed：t1/2β (3.48±0.92 h， k(0.21±0.06 h-1， 12 h accumulation of excretion percentage was (22.08±21.55%. CONCLUSION The pharmacokinetic profiles in SICU severe patients were different from pharmacokinetic profiles of normal population reported by researches before. SICU severe patients should be administrated individually with TDM，and the treatment should be adjusted timely， to guarantee safety and validity.
SUN N;ZHNG Zhen-yu;N You-zhong;ZHNG Chun-yn;GU Jin.
Pharmacokinetics of Norvancomycin of SICU Patients[J]. Chinese Pharmaceutical Journal, 2011, 46(3): 221-223
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] WANG B，JIANG H，LI X Q，et al. The effect of norvancomycin on the infections of MRS and the evaluation of the bacteriolagical investigation[J]. Chin J Antibiot(中国抗生素杂志，2001, 26(3：187. [2] WU L W. Therapeutic Drug Monitoring(治疗药物监测 [M]. Beijing：People′s Medical Publishing House，1989：410. [3] SUN H. Treatment of surgical severe patients[J]. Chin J Pract Surg(中华实用外科学杂志， 2001，21（4：235-237. [4] BALRAM C，LIM B L，LEE E J，et al. Validity of bayesian forecasting programme in therapeutic drug monitoring of vancomycin in a surgical intensive care unit：a prospective evaluation[J]. Ann Acad Med Singapore，1996，25(4：492-495. [5] WAN L L，YU Q，LI Y，et al. Dtermination of vancomycin and norvancomycin in serum[J]. Chin Pharm J（中国药学杂志，2008，11(8：998-1000. [6] LIN C，LIU S Q，DAI Q， et al. Determination of demethylvancomycin in renal dialysate effluent in burns with continuous renal replacement therapy[J]. Pharm J Chin PLA(解放军药学学报，2004，20(1：73-74. [7] ZHANG X L. Clinical Drug Reference(药物临床信息参考 [M]. Vol 4. Sichuan：Sichuan Science and Technology Publishing House，2006：192. [8] LI W S，WANG G L，YU Y H. Clinical Fluid Therapy(临床液体治疗学[M]. Beijing：Chemical Industry Press，2007：103. [9] ZHANG C，ZHAI S D，LIU F. Necessarity of therapeutic drug monitoring of vancomycin in clinical use：a systematic review[J]. Chin J Clin Pharmacol(中国临床药理学杂志，2009，25(4：329-333. [10] LEE P，DIPERSIO D，JEROME R N，et al. Approaching and analyzing a large literature on vancomycin monitoring and pharmacokinetics[J]. J Med Libr Assoc，2007，95（4：374-380.
PDF(517 KB)
